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Mouse Y1 adrenocortical cells
K-Ras
Protein kinase CThe neurohypophyseal hormone arginine vasopressin (AVP) is a classic mitogen in many cells. In K-Ras-
dependent mouse Y1 adrenocortical malignant cells, AVP elicits antagonistic responses such as the activation
of the PKC and the ERK1/2 mitogenic pathways to down-regulate cyclin D1 gene expression, which induces
senescence-associated β-galactosidase (SA-βGal) and leads to cell cycle arrest. Here, we report that in the
metabolic background of Y1 cells, PKC activation either by AVP or by PMA inhibits the PI3K/Akt pathway and
stabilises the p27Kip1 protein even in the presence of the mitogen ﬁbroblast growth factor 2 (FGF2). These
results suggest that p27Kip1 is a critical signalling node in the mechanisms underlying the survival of the Y1
cells. In Y1 cells that transiently express wild-type p27Kip1, AVP caused a severe reduction in cell survival, as
shown by clonogenic assays. However, AVP promoted the survival of Y1 cells transiently expressing mutant
p27-S10A or mutant p27-T187A, which cannot be phosphorylated at Ser10 and Thr187, respectively. In
addition, PKC activation by PMA mimics the toxic effect caused by AVP in Y1 cells, and inhibition of PKC
completely abolishes the effects caused by both PMA and AVP in clonogenic assays. The vulnerability of Y1
cells during PKC activation is a phenotype conditioned upon K-ras oncogene ampliﬁcation because K-Ras
down-regulation with an inducible form of the dominant-negative mutant H-RasN17 has resulted in Y1 cells
that are resistant to AVP's deleterious effects. These data show that the survival destabilisation of K-Ras-
dependent Y1 malignant cells by AVP requires large quantities of the p27Kip1 protein as well as
phosphorylation of the p27Kip1 protein at both Ser10 and Thr187.748-Bloco 09i, Sala 922, Cep
2; fax: +55 11 3091 2186.
evier OA license.© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Arginine vasopressin (AVP) is a vasoactive, antidiuretic, neuroen-
docrine peptide hormone synthesised in the supraoptic (SON) and
paraventricular (PVN) nuclei of the hypothalamus [1,2]. The effects
caused by AVP are mediated by three G protein-coupled receptors
(GPCR): V1aR, which is found in the brain, liver, peripheral tissue and
vessel smooth muscle [3]; V1bR, which is found in pituitary
corticotrophs and the brain [4]; and V2R, which is found in renal
collecting ducts [5]. In addition to its classical endocrine functions
(e.g., regulation of antidiuresis, vasoconstriction and stress response),
AVP also regulates mitogenesis, cell survival and death [6,7]. Evidence
of the mitogenic activity of AVP comes mainly from studies of either
primary cultures or cell lines derived from peripheral tissues that
express V1aR receptors [8]. However, a recent report [9] shows that
elevated AVP levels in rats caused the proliferation of kidney tubular
cells via V2R and ERK phosphorylation while V1aR-expressing cellsfrom other tissues were not affected. On the other hand, other studies
have quantitatively analysed the phosphoproteome of cultured V2R-
expressing renal collecting duct cells and found that AVP stimulation
led to a reduction in the phosphorylation of mitogenic kinases, such as
ERK and cyclin-dependent kinases [10]. Thus, the roles of both AVP
and its receptors V1aR and V2R in mitogenic signalling are still not
completely understood and deserve more investigation from different
point of view.
Over the last decade, studies have found that AVP controls the
growth and proliferation of lung, adrenal, pancreatic, breast cancer
cells and normal cardiac cells [11–15]. In V1aR-expressing mouse Y1
adrenal malignant cells, we previously reported that AVP elicits two
antagonistic responses: ﬁrst, AVP down-regulates cyclin D1 mRNA
and protein, which leads to cell cycle arrest; second, AVP activates
PI3K, PKC and ERK1/2 mitogenic pathways [16]. In addition, we
demonstrated that the Y1 cell's anti-proliferative response to AVP is
mediated by RhoA GTPase, which causes the down-regulation of
cyclin D1 and induction of senescence-associated β-galactosidase
[14].
Here, we report that activation of PKC with PMA mimics the anti-
proliferative effect of AVP in Y1 adrenal cells, which is conditioned on
1439F.L. Forti, H.A. Armelin / Biochimica et Biophysica Acta 1813 (2011) 1438–1445the over-expression of the K-ras oncogene. According to themetabolic
background of Y1 cells, activation of PKC seems to inhibit the PI3K/Akt
pathway, leading to the stabilisation of p27Kip1 irrespective of a strong
mitogen presence, and inhibitors of PKC completely protect cells from
both PMA and AVP's toxic effects. Thus, p27Kip1 is the target of
mitogenic action in the mechanisms underlying the survival of the K-
Ras-dependent Y1 malignant cell. In addition, the effects of AVP on
p27Kip1 signalling are more complex than the effects of PMA on
p27Kip1 signalling; does not act solely on p27Kip1 protein stabilisation
mediated by PKC activation. AVP was able to differentially regulate
endogenous levels of p27Kip1 phosphorylation at Ser10 or Thr187 and
also increase the survival rate of Y1 cells that transiently express
either of the mutants p27-S10A or p27-T187A. Each of these mutants
impaired nuclear translocation and degradation of p27 due to their
inability to be phosphorylated at Ser10 and Thr187.
2. Materials and methods
2.1. Chemicals
Synthetic arginine vasopressin (AVP) peptide was purchased from
Sigma. Geneticin (G418), bisindolylmalimide (GF109203X), Go6983,
H-89, LY294002, dexamethasone, DMSO, lipofectamine, buffers,
protein ladders and other chemicals were obtained from Calbiochem,
Invitrogen and Sigma. Recombinant bovine FGF2 was prepared in the
laboratory of Dr. Angelo Gambarini, Instituto de Química (USP, São
Paulo).
2.2. Cell culture
Stocks from the parental mouse Y1 adrenocortical tumour cell line
[17] and Y1-transfectant clonal sub-lines carrying the dominant-
negative mutant H-rasN17 (Y1-RasN17 conditional clones) [18] were
grown in 10% FCS-DMEwithout or with 100 μg/mL G418, respectively.
The H-RasN17 mutant protein was induced in Y1-RasN17 conditional
clones with 0.5 μM dexamethasone, added 12 h before starting the
experiment, as previously described [18]. To arrest the cell cycle at the
G0/G1 boundary, exponentially growing cells were incubated for 48 h
in serum-free medium (SFM).
2.3. Phosphorylation analysis of ERK1/2 and AKT proteins
Cells were lysed in cold 62.5 mM Tris–HCl pH 6.8, 2% w/v SDS, 10%
glycerol, 50 mM DTT and 1% w/v bromophenol blue. Lysates were
sonicated for 2 min, boiled for 5 min and clariﬁed by centrifugation
(14000 rpm, 5 min, 4 °C). Then, 150 μg protein aliquots were loaded
on 10% SDS-PAGE gels. After electroblotting onto Hybond-C nitrocel-
lulose membranes using a semi-dry Bio-Rad apparatus, total ERK1/2
or phospho-ERK1/2 (Thr202/Tyr204) and total AKT or phospho-AKT
(Ser473) were detected with polyclonal speciﬁc rabbit antibodies
(Cell Signalling), followed by a secondary peroxidase-conjugated
anti-rabbit polyclonal antibody for chemiluminescent detection (ECL,
Amersham-Pharmacia). Ponceau staining of the electroblotted mem-
brane was used to visually conﬁrm the efﬁciency of protein transfer.
2.4. Levels of p27Kip1 protein
Cells were lysed in 20 mM Tris–HCl pH 8.0, 135 mM NaCl, 10%
glycerol, 1% Nonidet P-40, 1 mM sodium orthovanadate, 2 μg/mL
leupeptin, 2 μg/mL aprotinin, and 2 μg/mL pepstatin. After quantita-
tion by the Bradford assay, aliquots of 150 μg proteinweremixedwith
SDS-PAGE sample buffer, loaded onto 10% SDS-PAGE gels and
processed for Western blotting for the AKT/PKB protein using a rabbit
polyclonal antibody monospeciﬁc for mouse p27Kip1 as well as
phosphorylated p27Kip1–Ser10 and p27Kip1–Thr187 (Santa Cruz).Ponceau staining of the electroblotted membrane was used to visually
conﬁrm an efﬁcient protein transfer.
2.5. Clonogenic assays
Parental Y1 cells and Y1 transfectant clonal lines were plated in
60 mm plates (1–5×103 cells/plate) containing 10% FCS/DME (with
or without 100 μM G418, as required) and maintained in culture
overnight. Afterwards, the cells were submitted to AVP, PMA and/or
FGF2 stimulation with or without 1 h of pre-treatment with speciﬁc
PKC inhibitors. Triplicate plates from each cell line were then washed
2× with PBS, 1× with DMEM, reefed with 10% FCS/DME medium and
returned to the incubator for 10–15 days or until colonies were
visualised. The medium was changed every 2–3 days and cells were
ﬁxed by PBS/10% formaldehyde solution at room temperature for
15 min and then washed 3× with PBS. The cell colonies were stained
with a 0.5% crystal violet solution for 4 h and then washed in
streaming water. Results are presented as the average of three
independent experiments.
2.6. Transient transfection of Y1 cells with p27Kip1 constructs
A total of 104 Y1 cells were seeded in 12 multiwell plates (~75%
conﬂuence) containing DME/10% FCS and incubated at 37 °C/5% CO2.
Cells were transfected 24 h later with 10 μg of plasmid DNA
harbouring the p27Kip1 wild-type, constructs S10A or T187A (kindly
donated by Dr. Christopher McAndrew from Prof. Dr. Daniel
Donoghue's laboratory, Department of Chemistry and Biochemistry,
UCSD, San Diego, CA) added to 500 μL of DME medium without
antibiotics or serum. Then, 100 μL of DMEmediumwithout antibiotics
or serum plus 10 μL of Lipofectin was prepared. Both solutions were
left at room temperature for 30–45 min. They were then mixed
together and incubated for an additional 15 min. The plasmid plus
Lipofectin mixture was added to previously washed cell plates
dropwise and placed in an incubator at 37 °C/5% CO2 for 6 h for cell
transfection. DME/10% FCS was added to the medium and plates were
incubated for another 24 h. Afterwards, the medium in the plates was
changed to fresh DME/10% FCS plus 10−9 M AVP (ﬁnal concentration)
and incubated for another period of 24 h. Plates were then washed
three times by PBS, refed with DME/10%FCS and changed every 3 days
until visualisation of countable colonies. The surviving colonies were
then treated and counted according to the previous protocol for the
clonogenic assay.
2.7. Statistics
The number of colonies per plate found in independent experi-
ments was pooled and statistically analysed by the Chi square (χ2)
test with pb0.05. Pairing of the AVP, PMA, and/or FGF2 treated/
untreated samples or clonal/parental cell lines was used to assess
statistical signiﬁcance.
3. Results
3.1. AVP or PMA irreversibly inhibits the proliferation of
K-Ras-dependent Y1 malignant adrenocortical cells by a
process completely dependent on PKC activity
Clonogenic assays showed that 24 h treatments of either AVP or its
mimicking agent PMA, a cell-permeable and direct activator of PKC,
strongly inhibited the development of colonies of mouse Y1
adrenocortical cells growing in DME containing 10% FCS (Fig. 1).
The speciﬁc PKC inhibitor Go6983 or bisindolylmaleimide GF109203X
(not shown) completely protects Y1 cells from AVP and PMA (Fig. 1),
implying that this inhibition of proliferation is entirely dependent on





















Fig. 1. Clonogenic assays showing thatAVPandPMAblockcolony formationofY1cells, but
pre-treatment with PKC inhibitors blocks these inhibitory effects. Parental Y1 cells were
plated (104 cells/plate of 60 mm diameter) and were pre-treated or not 24 h later with
10 μM Go6983 and ﬁnally with 1 nM AVP or PMA 10 ng/mL for 24 h. The medium was
changed to fresh 10% FCS/DME every third day. Results of colonies/plate from three
independent experiments were pooled and statistically analysed by χ2 with 1 degree of
freedom, pb0.005. Thepanel histogramdisplays averagesof colonies/platewith error bars.
1440 F.L. Forti, H.A. Armelin / Biochimica et Biophysica Acta 1813 (2011) 1438–1445The mouse Y1 adrenocortical cell line displays tight control of G0/
G1→S transition of cell cycle and is a relevant and useful model for
studying cell cycle regulation by AVP because it only expresses the
V1a receptor as measured by quantitative RT-PCR (P. Asprino and H.
Armelin, unpublished results). However, we previously reported that
the Y1 cell line exhibits a malignant phenotype dependent on
chronically elevated levels of K-Ras-GTP, which cause constitutive
activation of the PI3K/AKT pathway [18–20]. These high levels of K-
Ras-GTP also make Y1 cells prone to inhibition of proliferation by AVP
and PMA, a conclusion supported by the results of Fig. 2. A stable Y1
transfectant sub-line carrying the dominant-negative mutant H-
rasN17 under the control of the mouse mammary tumour virus [18]
was previously treated with 0.5 μMdexamethasone for 12 h to induce
the H-rasN17 transgene, causing a reduction in endogenous levels of
K-Ras-GTP. This reduction, in turn, rendered Y1-RasN17 cells resistant
to inhibition of proliferation by both AVP and PMA (Fig. 2), while
parental Y1 cells were not affected by dexamethasone treatment (not
shown).
To gain insight into the molecular mechanisms underlying these
phenomena, we probed signalling pathways involving PKC, AKT and































Fig. 2. Clonogenic assays showing that AVP and PMA inhibit colony formation in Y1 cells
and Y1-RasN17 mutant clones, but not in Y1-RasN17 induced by dexamethasone. Y1
cells and clones were plated (104 cells/plate of 60 mm diameter) and were pre-treated
(Y1-RasN17 clone 3.1) or not with 0.5 μM dexamethasone for 24 h and ﬁnally with
1 nM AVP or 10 ng/mL PMA for a subsequent 24 h. The medium was changed to fresh
10% FCS/DME every third day. Results of colonies/plate from three independent
experiments were pooled and statistically analysed by χ2 with 1 degree of freedom;
*, pb0.001; **, pb0.005. The panel histogram displays averages of colonies/plate with
error bars.tion, which peaked at 5 min (Fig. 3A) and began decreasing at 10 min
(Fig. S1A and B); AVP stimulation of ERK1/2 was partially reduced by
PKC inhibitors (Fig. 3A). PMA (10 ng/mL) also stimulated phosphor-
ylation of ERK1/2, but as expected, PKC inhibitors completely blocked
this PMA activity (Fig. S1A and B). Thus, although activation of PKC
was sufﬁcient for promoting ERK1/2 phosphorylation, both AVP and
FGF2 also stimulated ERK1/2 phosphorylation by pathways that were
independent of PKC. It is worth to mention that all effects of FGF2 in
Y1 cells are completely abolished by the FGFR tyrosine-kinase speciﬁc
inhibitor, PD173074 [Costa et al. (2008) Cancer Res], and are very
likely mediated by the FGFR1IIIc and FGFR2IIIc receptors (detected in
these cells by both quantitative RT-PCR and sequencing analyses of
RT-PCR-ampliﬁed fragments; J. Salotti and H.A. Armelin, unpublished
results).
However, the interactions between AVP, PMA and FGF2 regulate
the levels of phosphorylated AKT in a complex manner. We have
previously shown that FGF2 up-regulates the basal levels of phospho-
AKT in Y1 cells [20]. This up-regulation effect of FGF2 is inhibited by
PMA (Fig. S1B). Again, as expected, PMA inhibition of the FGF2 up-
regulation of phospho-AKT was completely abolished by PKC in-
hibitors (Fig. S1B) without interfering with basal levels of phospho-
AKT. It is worth emphasising that the speciﬁc inhibitor PI3K,
LY294002, totally eliminated bands of phospho-AKT (Fig. 3A),
implying that phospho-AKT is under a high and constant rate of
dephosphorylation and suggesting that steady levels of phospho-AKT
depend on a balance between PI3K activity and a phosphatase activity.
Thus, FGF2 very likely up-regulates phospho-AKT steady state levels
by increasing PI3K activity, a step that is antagonized by PKC
activation by PMA (Fig. S1B). On the other hand, AVP exerts a dual
regulatory role on steady state levels of phospho-AKT. AVP is a strong
inhibitor of phospho-AKT up-regulation by FGF2 (Fig. S2B), mimick-
ing PMA. Intriguingly, this inhibition of the up-regulatory effect of
FGF2 is stronger at lower concentrations of AVP, i.e., 10−9 to 10−10 M
(Fig. S2C), suggesting a speciﬁcity very likely mediated by V1A
receptors. Coherently with this interpretation, the antagonism of AVP
over the up-regulatory effect of FGF2 is independent of PKA activity
(Fig. 3B), a response expected from cells that do not express AVP-V1B
receptors. However, in the presence of PKC inhibitors, AVP resembled
FGF2 up-regulating phospho-AKT steady state levels (Fig. 3A), an
effect additive to that of FGF2 (Fig. S2A). Altogether, these results
suggest that AVP initiates two parallel antagonistic pathways: ﬁrst,
AVP activates PKC, which inhibits PI3K/Akt; second, AVP directly
stimulates PI3K/Akt.
3.2. AVP both increases stability in and promotes phosphorylation
of p27Kip1 in G0/G1-arrested Y1 cells stimulated by FGF2
We analysed p27Kip1 expression in Y1 cells to further investigate
themolecular basis of the antagonism between AVP andmitogens like
serum and FGF2. We previously reported that G0/G1-arrested Y1 cells
displayed high basal levels of p27Kip1, which were down-regulated by
treatment with serum or FGF2 [18]. Here, we show that AVP
maintained p27Kip1 at high levels for 24 h irrespective of the presence
of FGF2 (Fig. 4A), and this antagonistic effect of AVP was mimicked by
PMA (Fig. 4B). In addition, inhibitors of PKC completely blocked the
stabilising effect that PMA has on p27Kip1 levels but did not block the
effect that AVP has on p27Kip1 levels (Fig. 4B). Presumably, the
antagonistic effects of PMA on the FGF2 down-regulation of p27Kip1
levels are mediated by the inhibition of the PI3K/Akt pathway.
Conversely, AVP very likely promotes stabilisation of p27Kip1 levels by
two parallel methods, i.e., (a) inhibition of the PI3K/Akt pathway and
(b) via another pathway independent of PI3K/Akt. Thus, in the
presence of PKC inhibitors, AVP caused the up-regulation of AKT
(Fig. 3A and Fig. S2A) and also enhanced the up-regulation of AKT by
FGF2 (Fig. S2A). However, despite up-regulating AKT (Fig. 3A), AVP
was able to maintain high levels of p27Kip1 in the presence of PKC
Go6983 1µM30min +
AVP 1nM5min   + + + +
Bisindolylmaleimide 5µM 30min +   + + +
+ +   +
LY294002 20µM 30min + + +   +
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+   +
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Fig. 3. Activation of ERK1/2 and AKT by AVP and FGF2 in the presence of PKC, PI3K and PKA inhibitors monitored by Western blotting. Parental Y1 cells G0/G1-arrested by 48 h of
serum deprivation were pre-treated for 0.5 h with PKC (bisindolylmaleimide or Go6983) and PI3K (LY294002) inhibitors (A) or PKA (H-89) inhibitor (B) and stimulated with AVP
and/or FGF2 at the indicated times; lysates obtained were quantiﬁed by Bradford assay and probed against phospho-ERK1/2 and phospho-AKT. The Westerns shown are
representative of three independent experiments, which were quantiﬁed by densitometry and averaged to generate the histograms displayed in the panel; statistic signiﬁcance by
the F-test or ANOVA; *, pb0.01; **, pb0.05.
1441F.L. Forti, H.A. Armelin / Biochimica et Biophysica Acta 1813 (2011) 1438–1445inhibitors (Fig. 4B). Therefore, in the presence of PKC inhibitors, AVP/
V1aR and FGF2/FGFR signalling axes resemble each other in regard to
activation of both ERK1/2 and PI3K/Akt mitogenic pathways, but their
effects on p27Kip1 activity are different.
Regulation of p27Kip1 activity is known for being exerted on both
protein stability and subcellular location. Phosphorylation of p27Kip1
at Thr187 is the only p27Kip1 covalent modiﬁcation recognised and
bound by ubiquitin ligase for subsequent degradation, whereas
phosphorylation of p27Kip1 at Ser10, which is catalysed by both
nuclear kinases and AKT, labels p27Kip1 so that it can be exported from
the nucleus. Therefore, it became important to analyse p27Kip1
phosphorylation in Y1 cells submitted to AVP, FGF2 or AVP+FGF2.
Thus, G0/G1-arrested Y1 cells stimulated to progress across the G1
phase by serum (not shown) or FGF2 displayed(a) high levels of
p27Kip1 phosphorylated at Thr187 up to 5 h, which decreased
between 8 and 12 h and went up again by 24 h (Fig. 5A) and (b)
increased levels of p27Kip1 phosphorylated at Ser10 after 8 h (Fig. 5B).
These results are consistent with the principle that FGF2 promotes
AKT activation with consequent phosphorylation of p27Kip1 at both
Thr187 and Ser10, leading to, respectively, degradation and relocation
of p27Kip1 from the nucleus to the cytoplasm, allowing G1 phase
progression. Noticeably, AVP also regulates p27Kip1 phosphorylation
at both Thr187 (Fig. 5A) and Ser10 (Fig. 5B) but with a different,
antagonistic pattern compared to FGF2.3.3. AVP promotes survival of Y1 cells ectopically expressing p27Kip1
that are mutated at Ser10 or Thr187
The mutants p27-S10A and p27-T187A as well as the wild-type
p27Kip1-WT were ectopically expressed in Y1 cells to test the
hypothesis that p27Kip1 stabilisation underlies AVP's inhibition of Y1
cell proliferation. Plasmid constructs containing p27Kip1-WT, p27-
S10A and p27-T187A were transiently transfected into Y1 cell
cultures, either treated or untreated with AVP, for 24 h. Afterwards,
they were incubated in fresh medium until they developed visible
colonies (Fig. 6). When compared with mock-transfected control
cultures, the numbers of surviving colonies in the Y1 cells transfected
with p27Kip1-WT, S10A or T187A were reduced by 56%, 70% and 83%,
respectively (Fig. 6). These results were expected because transient
ectopic expression of p27Kip1-WT, p27-S10A and p27-T187A should
cause respectively the inhibition of cell growth and likely reduction of
cell viability. In addition, AVP treatment reduced the number of
surviving colonies in both mock-transfected controls and Y1 cells
transfected with p27Kip1-WT (Fig. 6). These results were also
expected; the results conﬁrmed the hypothesis that AVP inhibits
Akt activation by mitogens like FCS or FGF2, changing pattern of
p27Kip1 phosphorylation at both Ser10 and Thr187 (Fig. 5) and leading
to p27Kip1 stabilisation (Fig. 4). However, AVP treatment surprisingly
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Fig. 4. p27Kip1 levels in G0/G1-arrested Y1 cells by serum deprivation and stimulated with AVP, PMA and/or FGF2. Cellular lysates quantiﬁed by Bradford assay were probed against
total p27Kip1 protein and show that AVP and FGF2 differently affect the stability or expression of p27Kip1 (A), while PMA has similar effects to those of AVP (C), which are both
inhibited by PKC inhibitors (B). Blots shown are representative of three independent experiments, which were quantiﬁed by densitometry and averaged to generate the histograms
displayed in the panel; statistic signiﬁcance by the F-test or ANOVA; *, pb0.01; **, pb0.05.
1442 F.L. Forti, H.A. Armelin / Biochimica et Biophysica Acta 1813 (2011) 1438–1445the mutants p27-S10A or p27-T187A, which cannot be phosphory-
lated at Ser10 and Thr187, respectively, as shown by the two-fold
increase in the number of surviving colonies in both cases (Fig. 6).
Thus, the effect of AVP on Y1 cell survival is dependent on which type
of p27Kip1 a cell expresses.
4. Discussion and conclusion
For almost 20 years, regulation of mitogenesis and cell survival by
the AVP/V1aR signalling system has been studied in both primary
cultures and cell lines derived from multiple peripheral tissues [6–8].
The main purpose of this study was to investigate the interaction
between the p27Kip1 protein and PKC and PI3K/Akt signalling
pathways in both pro-senescence and anti-proliferative responses,
which are triggered by the AVP/V1aR axis, in mouse malignant Y1
adrenocortical cells. Thus, we hypothesized that, in addition to the
down-regulation of the cyclin D1, the increase of the cell cycle
inhibitor p27Kip1, as reported in studies on the anti-proliferative
effects of ACTH in Y1 cell line [18], might be another putative target of
AVP acting against the oncogenic ras-driven proliferation of these
cells. We have shown that AVP triggers two antagonistic responses in
V1aR-expressing mouse Y1 adrenal malignant cells: (a) it activatesthe PI3K/Akt, PKC and ERK1/2 mitogenic pathways [16], and (b) it
concomitantly activates RhoA GTPase, causing down-regulation of
cyclin D1, induction of senescence-associated β-galactosidase and cell
cycle arrest [14,16].
Here, we explored both PMA and AVP signalling in the metabolic
background of K-Ras-dependent Y1 adrenocortical cells to show that
activation of PKC with PMAmimics the effect of AVP, and inhibitors of
PKC completely protect cells from both PMA and AVP toxic effects in
clonogenic assays (Fig. 1). The responsiveness of Y1 cells to PKC
activators is phenotypically dependent on Ki-ras oncogene ampliﬁ-
cation because K-Ras-GTP down-regulation by ectopic expression of a
dexamethasone-inducible form of the dominant-negative mutant H-
RasN17 abolishes the toxic effects of both PMA and AVP (Fig. 2). To
uncover the molecular signalling mechanisms underlying these
phenomena, we analysed the outcome of ERK, PKC and PI3K/Akt
activation in Y1 malignant cells. Thus, AVP activated ERK1/2 despite
PKC activity, but inhibitors of PKC reduced the AVP's degree of ERK1/2
activation (Fig. 3A); however, AVP had a dual effect on the PI3K/Akt
pathway. First, AVP inhibited PI3K/Akt via PKC activation (Fig. 3B);
however, if PKC was blocked by speciﬁc inhibitors, AVP activated the
PI3K/Akt pathway like a bona ﬁde mitogen (Fig. 3B). Second, PMA,
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Fig. 5. Phosphorylation levels of p27Kip1–Ser10 or p27Kip1–Thr187 in G0/G1-arrested Y1 cells stimulated with AVP and/or FGF2. Cellular lysates obtained at the indicated times after
AVP±FGF2 stimuli were assayed byWestern blotting against p27Kip1–phospho-Thr187 (A) or p27Kip1–phospho-Ser10 (B) and showed different patterns of protein levels as the cells
transitioned through the cell cycle phases. The Westerns shown are representative of three independent experiments, which were quantiﬁed by densitometry and averaged to
generate the histograms displayed in the panel; statistic signiﬁcance by the F-test or ANOVA; *, pb0.01; **, pb0.05.
1443F.L. Forti, H.A. Armelin / Biochimica et Biophysica Acta 1813 (2011) 1438–1445phosphorylation of ERK1/2 and inhibited PI3K/Akt activation (Fig. S1A
and B). Inhibitors of PKC abolished the effects of PMA on both ERK1/2
and PI3K/Akt. These results indicate that chronic high levels of K-Ras-
GTP, as found in Y1 cells [18], lead to a malignant phenotype in which
PKC is a target that inhibits the up-regulation of the PI3K/Akt pathway
when activated and thus reduces both cell proliferation and survival.
By these molecular mechanisms, AVP stabilises and/or increases the
expression of the p27Kip1 protein (Fig. 4C) to arrest the cell cycle and
to antagonize the mitogenic activity of FGF2 or serum. Therefore,
p27Kip1 seems to be a critical signalling node in the molecular
mechanisms underlying the survival vulnerability of K-Ras-depen-
dent malignant cells. It is interesting to note that p27Kip1 is the target
of the anti-proliferative mechanisms of two distinct peptide hor-
mones: AVP, as is discussed in this paper, and ACTH [18]. Moreover,
similar anti-proliferative mechanisms involving both the PI3K–Akt
pathway and the p27Kip1 protein were recently reported in mouse
models of K-Ras-driven urethane lung tumours [21].
We previously have shown that AVP blocked the expression of
cyclin D1 mRNA and protein induced by FGF2 in G0/G1-arrested Y1
cells [16]. In this paper, we are extending this investigation to show
that AVP, under the same conditions, also maintains high levels of
p27Kip1 protein. These results suggest that AVP must simultaneously
cause both blocking of cyclin D1 expression and p27Kip1 stabilisation
to achieve irreversible cell cycle arrest and the reduction of survival in
Y1 adrenal malignant cells. However, we also reported that ectopic
over-expression of cyclin D1 was sufﬁcient to render Y1 cells
completely resistant to the noxious effects of AVP [16]; this
observation does not contradict the idea that irreversible Y1 cell
cycle arrest requires both the blocking of cyclin D1 expression and
p27Kip1 stabilisation because the ectopically expressed cyclin D1,
when coupled to CDKs, presumably interacts with p27Kip1 to yield
neutralised complexes in a cell nucleus [22–25].However, the effects of AVP on p27Kip1 signalling seem more
complex than simple p27Kip1 protein stabilisation mediated by PKC
activation (Fig. 4) or by differential post-transcriptional regulation of
key phosphorylation sites (Fig. 5). In Y1 cells that transiently and
ectopically express wild-type p27Kip1, AVP caused a signiﬁcant
reduction in cell survival, as shown by clonogenic assays (Fig. 6).
Conversely, AVP promoted the survival of Y1 cells by transiently
expressing either of the mutants p27-S10A or p27-T187A, neither of
which can be phosphorylated at Ser10 and Thr187, respectively
(Fig. 6). Thus, Y1 cells recognise AVP as a survival factor when
endogenous p27Kip1 is replaced by exogenous mutated p27Kip1 with
an altered afﬁnity for speciﬁc cyclin–CDK complexes, stability and
subcellular localisation [26,27].
Support for the concept of p27Kip1 dual role in both tumour
suppression and tumour promotion has been established in recent
years. Thus, the suppressor role of p27Kip1 was ﬁrst demonstrated by
the increased susceptibility of p27Kip1-deﬁcient mice to develop
tumours [28–31]. However, the CDKN1B gene that encodes p27Kip1 is a
notable exception to the classic tumour suppressor gene paradigm
because it is rarely mutated in tumours [32,33]. Instead, reduced
levels of the p27Kip1 protein, or cellular mislocalisation, correlate with
tumour aggressiveness and poor prognosis [34]. However, speciﬁc
cases of cancers in the breast, thyroid, oesophagus and colon were
found that displayed nuclear p27Kip1 exportation to the cytoplasm,
suggesting that cytoplasmic mislocalisation of p27Kip1 may be
important for tumour progression [35]. In summary, while tumour
suppressor activity is activated in normal cells in response to anti-
proliferative signals, thus tilting the balance towards cell cycle
blockage and inhibition of proliferation, tumour cells have developed
strategies to down-regulate these functions of p27Kip1. However,
other activities that appear to be pro-tumourigenic are neither
affected nor even enhanced, which results in a stimulation of tumour































Fig. 6. Clonogenic assays of Y1 cells ectopically expressing wild-type p27Kip1 and its mutants show that AVP effects depend on the levels and status of phosphorylated forms of
p27Kip1. Y1 cells (2×104) were plated in six-well plates and lipofected 24 h later with WT–p27Kip1, p27Kip1–S10A and p27Kip1–T187A constructs for 6 h. After returning cells to 10%
FBS-containing medium and another 24 h of recovery, the cells were stimulated with 1 nM AVP for 24 h. The mediumwas changed every third day until colonies developed. Results
of colonies/plate from three independent experiments were pooled and statistically analysed by χ2 with 1 degree of freedom; *, pb0.05; **, pb0.01; ***, pb0.001. The panel
histogram displays averages of colonies/plate with error bars; upper panel displays averages of colonies/plate.
1444 F.L. Forti, H.A. Armelin / Biochimica et Biophysica Acta 1813 (2011) 1438–1445development. The p27Kip1 balance is regulated by multiple post-
translational modiﬁcations that affect its function by altering in-
teractions between proteins, affecting subcellular localisation and
modulating protein stability. This study further demonstrates the dual
roles of the p27Kip1 protein and relates the dual roles of AVP signalling
to mouse tumour cells.
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